Guo et al. [24] showed that the inhibition of WEE1 activates interferon pathways (the cGAS/STING and ERV/dsRNA pathways) to promote tumor immune responses in ovarian cancer and that combination therapy with WEE1 inhibitors and immune checkpoint inhibitors is effective. Here, WEE1 is linked to ovarian carcinoma.